Merck KGaA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Merck KGaA with three other
pharmaceutical manufacturers in Europe:
Novo Nordisk As
sales of 126.95 billion Danish Kroner [US$19.79 billion]
of which 85%
was Diabetes and obesity),
(5.35 billion Euros [US$6.20 billion]
of which 34%
was Cimzia), and
based in UNITED KINGDOM
(£20.59 billion [US$28.37 billion]
of which 41%
During the second
quarter of 2021, sales at Merck KGaA totalled
4.87 billion Euro.
an increase of 18.2%
from the 4.12 billion Euro in sales at the company during the second quarter of 2020.
This was the largest same quarter increase in sales since the third
quarter of 2016.
During the first two
quarters of 2021, sales totalled 9.50 billion Euro, which is
than through the first two quarters of 2020.
During the previous 12 quarters, sales at Merck KGaA have increased compared with the same quarter in the previous year.
Merck KGaA reported sales of 17.53 billion Euro (US$20.34 billion)
December of 2020.
increase of 8.6%
versus 2019, when the company's sales were 16.15 billion Euro.
Sales of Electronics saw an increase
that was more than double the company's growth rate: sales were up
31.3% in 2020, from
2.57 billion Euro to 3.38 billion Euro.
Not all segments of Merck KGaA experienced an increase in sales in 2020:
sales of Healthcare fell 1.1% to 6.64 billion Euro.